Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep

Phase 3positivebitopertinPositive

AI Analysis

Summary

Disc Medicine's bitopertin, rejected by the FDA in February, met its Phase 3 goals in erythropoietic protoporphyria, significantly reducing a key disease biomarker and increasing time patients could spend in sunlight and artificial light. The results set up a potential FDA resubmission.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Bitopertin significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria could spend in sun and artificial light; sets up a potential FDA resubmission after the February rejection.

Importance:7/10

Sentiment:

0.60

Phase 3EPPrare diseasebitopertinFDA rejectionresubmissionclinical trial results

Related Companies

$SHWZ

Read the original article

Published by BioSpace on October 19, 2026 11:02 AM

Read Original